Sorafenib (Nexavar)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: RAF1, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2006-07-19: Initial marketing authorization as Nexavar

History of changes in Health Canada indication

  • 2006-07-28: Initial notice of compliance with conditions
  • 2009-06-12: Conditions were met

Also known as

  • Code names: BAY 43-9006, BAY 54-9085
  • Brand names: Nexavar, Sorafenat, Soranib